Flagship Ventures Dives Into Microbiome, Launches Seres Health
This article was originally published in The Pink Sheet Daily
Only a few biopharmaceutical start-ups have formed in the emerging microbiome space, but VC firm Flagship says its homegrown Seres Health, still somewhat stealthy, is developing a new category of drugs that aim to rebalance microbiome populations causing disease.
You may also be interested in...
Deal Watch: Flagship Ventures Doubles Down On Microbiome
Two of the VC's biotechs merged to create an immuno-microbiome company, while Seres is working with Emulate on better tech for microbiome research. UK specialty pharma Martindale acquired small hospital products-focused UK firm Viridian, and Bayer and X-Chem expanded their drug discovery alliance.
Venture Creation Story: The Early Days Of Moderna
From pioneering stem-cell work to trade secrets a la Coca-Cola, what it means when a company – in this case, the RNA therapeutics developer Moderna – comes through Flagship Ventures’ VentureLabs group.
Moderna To Focus On Messenger RNA Approaches To Recreate Therapeutic Proteins
The latest biotech to emerge from Flagship Ventures’ incubator is Moderna, which plans to focus on rare diseases in-house while out-licensing its technology for larger indications.